Fluidda

Kontich, Belgium All Belgium companies → — Founded 2005

Biotech / Drug Discovery Imaging AI Specialist Specialty-Focused AI

Pulmonology Radiology

Radiology & Imaging AI

Claim this company

About Fluidda

Fluidda is a healthcare AI company that specializes in Functional Respiratory Imaging (FRI), a proprietary technology that combines high-resolution CT scans with computational fluid dynamics (CFD) and artificial intelligence. [1, 17] This approach allows for the creation of patient-specific 3D models of the lungs, providing detailed insights into lung structure, function, ventilation, perfusion, and even aerosol deposition. [1, 10, 15] For physicians, FRI offers a sensitive tool for phenotyping patients and monitoring the efficacy of novel respiratory drugs, going beyond traditional spirometry by visualizing small abnormalities and diffuse disease-related changes at a high resolution. [1, 8, 10]

Fluidda’s technology, including its Broncholab platform, is designed to improve the diagnosis, monitoring, and treatment optimization of various respiratory diseases such as asthma, COPD, cystic fibrosis, ARDS, ALI, idiopathic pulmonary fibrosis (IPF), pulmonary vascular disease, interstitial lung disease, and obstructive sleep apnea. [2, 3, 7, 8, 10, 13, 25] By providing quantitative outcome parameters, FRI can help physicians make more informed decisions, personalize treatment plans, and potentially reduce the need for extensive clinical endpoint studies in drug development. [5, 7, 10, 15] The company also offers contract research organization (CRO) services, leveraging its FRI technology to make clinical trials shorter, faster, and more cost-effective, requiring fewer patients to achieve significant results. [5, 15, 18]

Focus Areas

Functional Respiratory Imaging (FRI) respiratory disease diagnosis personalized medicine drug development clinical trials asthma COPD cystic fibrosis

Business Intelligence

Technology

cloud-native, AI-powered image analysis, computational fluid dynamics (CFD)

What Physicians Need to Know

Functional Respiratory Imaging (FRI)

Fluidda is a world leader in Functional Respiratory Imaging (FRI), a proprietary technology that combines high-resolution CT (HRCT) scans with Computational Fluid Dynamics (CFD) to create 3D models of the lungs. This allows for detailed, patient-specific analysis of lung function, structure, ventilation, and perfusion, offering insights beyond traditional pulmonary function tests like spirometry.

Respiratory Diseases & Personalized Medicine

Fluidda specializes in a wide range of respiratory conditions including asthma, COPD, cystic fibrosis, idiopathic pulmonary fibrosis (IPF), ARDS, ALI, pulmonary hypertension, and sleep-related breathing disorders. FRI provides a unique entry point into personalized medicine by optimizing diagnosis, monitoring disease progression, and assessing therapy effects at a regional level, which is crucial for understanding individual patient pathophysiology.

Drug & Device Development / Clinical Trials

Fluidda offers CRO services for drug and medical device development, leveraging FRI to make clinical trials shorter, faster, and more cost-effective. FRI's sensitive biomarkers can detect changes in the respiratory system caused by a drug more accurately and in fewer patients, potentially reducing the number of participants needed in trials. They also assist in device design and optimization using CFD and Finite Element Analysis (FEA) techniques.

Quantitative CT-based Imaging & Image Analysis

Fluidda utilizes quantitative CT (QCT) techniques, including HRCT, to extract numerical data from scans, providing detailed quantitative representations of lung images. Their image analysis extends to CT, MRI, PET, and SPECT, offering insights into lobe volumes, densities, emphysema and fibrosis scoring, airway and vascular measurements, and blood vessel density.

Computational Fluid Dynamics (CFD) & AI

Fluidda's core technology integrates Computational Fluid Dynamics (CFD), a discipline originating from aerospace engineering, to quantify airflow and exposure to inhaled particles within the lungs. They also incorporate Artificial Intelligence (AI) to perform fast and accurate calculations of new biomarkers, enhancing respiratory drug development and care.

Physician Tip

Fluidda's Functional Respiratory Imaging (FRI) and Broncholab platform offer physicians a powerful tool for personalized respiratory care. Unlike traditional spirometry, which provides a global view, FRI delivers regional information on lung function, structure, ventilation, and perfusion, enabling a deeper understanding of disease pathophysiology and guiding optimal treatment strategies. Physicians can use FRI to optimize diagnosis, monitor disease progression, assess the efficacy of therapies, and even predict the course of certain conditions like IPF and COVID-19. The platform provides quantitative CT-based metrics such as emphysema and fibrosis scoring, lobe volumes, and vascular analysis, all from a single chest CT scan, with rapid turnaround times. This detailed, regional data can help in making more informed decisions, especially in complex cases, and can facilitate early adjustments to therapy. Furthermore, FRI can assist in identifying patients who may benefit most from specific treatments, such as in COPD, and can help in understanding the impact of mucus on regional ventilation and airway resistance.

Fluidda's Broncholab platform, cleared by the FDA for clinical practice, provides FRI parameters to physicians via an online platform. The process involves acquiring low-dose HRCT scans, which are then sent to Fluidda for 3D reconstruction and analysis. The platform integrates advanced image processing with computational fluid dynamics and artificial intelligence to generate comprehensive reports. Fluidda also collaborates with healthcare professionals and pharmaceutical companies, offering CRO services and leveraging a worldwide database for clinical trials and research.

Products by Fluidda

No products listed for this company yet. Know of one? Suggest it →

What the Web Says

Fluidda is a company that has developed Functional Respiratory Imaging (FRI) technology, which utilizes advanced digital imaging and computational fluid dynamics to offer detailed 3D visualizations of lung conditions. This technology, including their FDA-cleared Broncholab software, is designed to enhance the diagnosis and monitoring of respiratory diseases, streamline drug development, and enable personalized treatment approaches. While direct employer or product reviews for 'Fluidda' were not found on general review sites like G2, Glassdoor, Capterra, or Reddit, healthcare IT and industry-specific sources highlight the innovative aspects and potential benefits of their FRI technology.

Overall: Positive

Strengths

Advanced 3D visualization of airways and lung geometry
Improved diagnosis and monitoring of respiratory diseases
Potential to optimize drug development and personalize treatment
FDA-cleared Broncholab software provides valuable biomarkers
Reduces the number of patients needed in clinical trials
Strong leadership team with diverse expertise

Limitations

Lack of readily available employer or product reviews on major platforms like G2, Glassdoor, Capterra, and Reddit

Based on reviews from: healthcaretechoutlook.com, fiercebiotech.com, auntminnie.com, technologynetworks.com, respiratory-therapy.com

Last updated: 2026-10-30

Videos

News, demos, and interviews about Fluidda.

Loading videos...

Videos load interactively. If none appear, search YouTube for Fluidda →

View all on YouTube

Press & Coverage

Oaklins

Banook, backed by Motion Equity, has acquired Fluidda

In November 2025, Banook Group acquired Fluidda NV, expanding its services into advanced in-silico trials and respiratory disease modeling. This acquisition combines Banook's expertise in cardiac safety and clinical data with Fluidda's AI-driven respiratory analytics, creating an integrated platform to strengthen Banook's position in the CRO sector.

2025-11

Banook

Banook acquires Fluidda to create a global leader in clinical trial services

On November 13, 2025, Banook acquired Fluidda, integrating Fluidda's Functional Respiratory Imaging (FRI) platform to enhance Banook's data analytics and imaging capabilities for complex global trials. This move strengthens the combined group's presence across Europe, North America, and Asia-Pacific, offering integrated endpoint management and imaging services in the growing respiratory clinical trial market.

2025-11

HigherGov

Fluidda Awarded Cooperative Agreement U01FD007987 from Center for Drug Evaluation and Research

Fluidda was awarded a Cooperative Agreement worth $996,903 from the Center for Drug Evaluation and Research in September 2023. The grant, with a duration of 4 years, is for a prospective study to support the validation of lung deposition models using nuclear medicine imaging methods.

2023-09

Fluidda

PRESS RELEASE – Fluidda and Aptar Pharma Exclusive Collaboration

Fluidda announced an exclusive collaboration with Aptar Pharma on September 22, 2022.

2022-09

Fierce Biotech

FDA clears Fluidda's digital lung imaging platform for respiratory disease monitoring

In March 2020, the FDA cleared Fluidda's Broncholab software, a digital imaging platform designed to provide insights into lung function for diagnosing and monitoring respiratory diseases. The platform uses high-resolution CT scans, computational fluid dynamics, and AI to offer more accurate and clinically relevant information than traditional lung function tests.

2020-03

AuntMinnie.com

FDA clears Fluidda respiratory imaging platform

The U.S. Food and Drug Administration (FDA) cleared Fluidda's functional respiratory imaging (FRI) online platform, Broncholab, on March 10, 2020. This platform provides FRI parameters to physicians to aid in the diagnosis and monitoring of respiratory diseases and to advance personalized medicine.

2020-03

Newswire.ca

FDA Clears Fluidda's Broncholab Platform for Use in Clinical Practice

On March 11, 2020, the US Food and Drug Administration provided market clearance to Fluidda for its Broncholab platform. Broncholab offers Functional Respiratory Imaging (FRI) parameters to physicians via an online platform to assist in diagnosing and monitoring respiratory diseases.

2020-03

MassDevice

FDA clears Fluidda's high-res respiratory imaging software

Fluidda announced on March 11, 2020, that the FDA cleared its Broncholab software, designed to assist in diagnosing and monitoring respiratory diseases for clinical use. The Broncholab platform provides functional respiratory imaging (FRI) parameters to physicians via an online platform, combining high-resolution CT, computational fluid dynamics, and AI technology.

2020-03

Frequently Asked Questions

What is Functional Respiratory Imaging (FRI) and how does Fluidda utilize it for respiratory disease diagnosis?

Functional Respiratory Imaging (FRI) is a proprietary technology developed by Fluidda that combines high-resolution CT (HRCT) scans with computational fluid dynamics (CFD) and artificial intelligence to create detailed, patient-specific 3D models of lung anatomy and function. This technology provides insights into airway geometry, lung volumes, airflow, and aerosol deposition, offering a more precise and quantitative assessment of lung health than traditional methods like spirometry. Fluidda's Broncholab platform, cleared by the FDA, uses FRI to provide physicians with parameters for diagnosing and monitoring respiratory diseases.

How does Fluidda's technology contribute to personalized medicine for respiratory conditions like asthma, COPD, and cystic fibrosis?

Fluidda's FRI technology provides a unique entry point into personalized medicine by optimizing diagnosis, monitoring disease progression, and assessing the effects of therapy. It allows for detailed regional lung functionality assessment, which helps in understanding the pathophysiology of individual patients and choosing optimal treatments for conditions such as asthma, COPD, and cystic fibrosis. This approach moves beyond the limitations of standard spirometry, which cannot differentiate between various disease phenotypes.

What role does Fluidda play in drug development and clinical trials for respiratory diseases?

Fluidda operates as a Contract Research Organization (CRO) and utilizes its FRI technology to enhance drug development and accelerate clinical trials for respiratory diseases. FRI can detect changes in the respiratory system caused by a drug more accurately and with fewer patients, potentially reducing the number of participants needed in clinical trials for conditions like asthma and COPD. The FDA has encouraged the use of FRI in clinical trials, particularly for Idiopathic Pulmonary Fibrosis (IPF), to expedite the development of new drugs and biomarkers.

What products or services does Fluidda offer to healthcare professionals and pharmaceutical companies?

Fluidda offers its proprietary Functional Respiratory Imaging (FRI) technology, including the Broncholab platform, which provides image analysis and project management services for clinical practice. For pharmaceutical and medical device organizations, Fluidda provides services such as imaging CRO, structural dynamics analysis, and personalized deposition modeling. These offerings support drug development, medical device validation, and patient diagnosis and monitoring.

What is the current status of Fluidda's company stability, partnerships, and regulatory compliance?

Fluidda was acquired by Banook Group in November 2025, strategically expanding Banook's capabilities in advanced in-silico trials and respiratory disease modeling. Fluidda continues to operate under its brand as part of Banook, maintaining its R&D centers in Belgium and Portugal. Fluidda's Broncholab platform received FDA clearance in March 2020, and the company has a history of FDA support for its FRI technology in clinical trials. They also have a collaboration with Nanopharm to accelerate FDA approvals for orally inhaled generic products.

Related Companies

Suggest an Edit → | Report an issue